JP2017515849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515849A5 JP2017515849A5 JP2016567529A JP2016567529A JP2017515849A5 JP 2017515849 A5 JP2017515849 A5 JP 2017515849A5 JP 2016567529 A JP2016567529 A JP 2016567529A JP 2016567529 A JP2016567529 A JP 2016567529A JP 2017515849 A5 JP2017515849 A5 JP 2017515849A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oral dosage
- dasotorarin
- dosage form
- adhd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000006186 oral dosage form Substances 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- YKXHIERZIRLOLD-DFIJPDEKSA-N (1r,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 YKXHIERZIRLOLD-DFIJPDEKSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- SRPXSILJHWNFMK-MEDUHNTESA-N dasotraline Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 claims 1
- 229950006987 dasotraline Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992619P | 2014-05-13 | 2014-05-13 | |
| US61/992,619 | 2014-05-13 | ||
| PCT/US2015/030357 WO2015175523A1 (en) | 2014-05-13 | 2015-05-12 | Dosage of dasotraline and method for treatment of adhd |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515849A JP2017515849A (ja) | 2017-06-15 |
| JP2017515849A5 true JP2017515849A5 (enExample) | 2018-06-21 |
Family
ID=54480549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567529A Pending JP2017515849A (ja) | 2014-05-13 | 2015-05-12 | Ａｄｈｄを治療するためのダソトラリン用量および治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10076503B2 (enExample) |
| EP (1) | EP3143000A4 (enExample) |
| JP (1) | JP2017515849A (enExample) |
| KR (1) | KR20170005088A (enExample) |
| CN (1) | CN106660937A (enExample) |
| AU (1) | AU2015259346A1 (enExample) |
| CA (1) | CA2948839A1 (enExample) |
| IL (1) | IL248847A0 (enExample) |
| MX (1) | MX2016014768A (enExample) |
| WO (1) | WO2015175523A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210386689A1 (en) * | 2018-10-31 | 2021-12-16 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4556676A (en) * | 1979-11-01 | 1985-12-03 | Pfizer Inc. | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
| PT1542961E (pt) * | 2002-09-16 | 2013-11-05 | Sunovion Pharmaceuticals Inc | Trans 4-(3,4-diclorofenil)-1,2,3,4-tetrahidro-1- naftalenamina para uso no tratamento de perturbações do sistema nervoso central |
| DK2506842T3 (en) * | 2009-12-04 | 2015-02-23 | Sunovion Pharmaceuticals Inc | Formulations, salts and polymorphs of transnorsertraline and their applications |
-
2015
- 2015-05-12 US US15/310,351 patent/US10076503B2/en active Active
- 2015-05-12 CA CA2948839A patent/CA2948839A1/en not_active Abandoned
- 2015-05-12 MX MX2016014768A patent/MX2016014768A/es unknown
- 2015-05-12 JP JP2016567529A patent/JP2017515849A/ja active Pending
- 2015-05-12 AU AU2015259346A patent/AU2015259346A1/en not_active Abandoned
- 2015-05-12 KR KR1020167034705A patent/KR20170005088A/ko not_active Withdrawn
- 2015-05-12 EP EP15792455.6A patent/EP3143000A4/en not_active Withdrawn
- 2015-05-12 WO PCT/US2015/030357 patent/WO2015175523A1/en not_active Ceased
- 2015-05-12 CN CN201580027353.3A patent/CN106660937A/zh active Pending
-
2016
- 2016-11-09 IL IL248847A patent/IL248847A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012193216A5 (enExample) | ||
| JP2015523407A5 (enExample) | ||
| MX2018008021A (es) | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. | |
| JP2013155188A5 (enExample) | ||
| JP2016163571A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2015057451A5 (enExample) | ||
| JP2015083580A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2015038135A5 (enExample) | ||
| JP2016147915A5 (enExample) | ||
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| JP2015537009A5 (enExample) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2013166781A5 (enExample) | ||
| JP2016527312A5 (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物 | |
| AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
| JP2018522028A5 (enExample) | ||
| FI2683245T4 (fi) | Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2017061488A5 (enExample) | ||
| JP2017515849A5 (enExample) | ||
| JP2015512948A5 (enExample) |